Clinical Trials Search
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients with Soft Tissue Sarcoma
This is a single-arm trial that will evaluate the feasibility and toxicities of the Tumor-infiltrating lymphocyte (TIL) treatment and the persistence of TIL survival in vivo following treatment.
The primary objective of this study will be to determine whether patients receiving adoptively transferred, tumor specific T cells after non-myeloablative, lymphodepleting chemotherapy followed by high dose IL-2 have acceptable side effects. Secondary objectives will include degree of sustained persistence of infused T cells and objective anti-tumor responses by RECIST v1.1 evaluations for tumor response
IL-2 (Interleukin-2); MESNA (); TIL (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)